<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:58:55Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7178627" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7178627</identifier>
        <datestamp>2020-04-24</datestamp>
        <setSpec>ascp</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Addict Sci Clin Pract</journal-id>
              <journal-id journal-id-type="iso-abbrev">Addict Sci Clin Pract</journal-id>
              <journal-title-group>
                <journal-title>Addiction Science &amp; Clinical Practice</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1940-0632</issn>
              <issn pub-type="epub">1940-0640</issn>
              <publisher>
                <publisher-name>BioMed Central</publisher-name>
                <publisher-loc>London</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7178627</article-id>
              <article-id pub-id-type="pmcid">PMC7178627</article-id>
              <article-id pub-id-type="pmc-uid">7178627</article-id>
              <article-id pub-id-type="pmid">32321570</article-id>
              <article-id pub-id-type="publisher-id">188</article-id>
              <article-id pub-id-type="doi">10.1186/s13722-020-00188-5</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Study Protocol</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9104-0670</contrib-id>
                  <name>
                    <surname>Murphy</surname>
                    <given-names>Sean M.</given-names>
                  </name>
                  <address>
                    <email>smm2010@med.cornell.edu</email>
                  </address>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jeng</surname>
                    <given-names>Philip J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Poole</surname>
                    <given-names>Sabrina A.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jalali</surname>
                    <given-names>Ali</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff1">1</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vocci</surname>
                    <given-names>Frank J.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gordon</surname>
                    <given-names>Michael S.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff3">3</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Woody</surname>
                    <given-names>George E.</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff2">2</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Polsky</surname>
                    <given-names>Daniel</given-names>
                  </name>
                  <xref ref-type="aff" rid="Aff4">4</xref>
                </contrib>
                <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.5386.8</institution-id><institution-id institution-id-type="ISNI">000000041936877X</institution-id><institution>Department of Population Health Sciences, </institution><institution>Weill Cornell Medical College, </institution></institution-wrap>425 East 61st Street, Suite 301, New York, NY 10065 USA </aff>
                <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.25879.31</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8972</institution-id><institution>Department of Psychiatry, Perelman School of Medicine, </institution><institution>University of Pennsylvania, </institution></institution-wrap>Philadelphia, PA USA </aff>
                <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.280676.d</institution-id><institution-id institution-id-type="ISNI">0000 0004 0447 5441</institution-id><institution>Friends Research Institute, </institution></institution-wrap>Baltimore, MD USA </aff>
                <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.21107.35</institution-id><institution-id institution-id-type="ISNI">0000 0001 2171 9311</institution-id><institution>Department of Health Policy and Management, Bloomberg School of Public Health, Carey Business School, </institution><institution>Johns Hopkins University, </institution></institution-wrap>Baltimore, MD USA </aff>
              </contrib-group>
              <pub-date pub-type="epub">
                <day>22</day>
                <month>4</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>22</day>
                <month>4</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <year>2020</year>
              </pub-date>
              <volume>15</volume>
              <elocation-id>15</elocation-id>
              <history>
                <date date-type="received">
                  <day>27</day>
                  <month>8</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>8</day>
                  <month>4</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2020</copyright-statement>
                <license license-type="OpenAccess">
                  <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
                </license>
              </permissions>
              <abstract id="Abs1">
                <sec>
                  <title>Background</title>
                  <p id="Par1">Persons with an opioid use disorder (OUD) who were incarcerated face many challenges to remaining abstinent; concomitantly, opioid-overdose is the leading cause of death among this population, with the initial weeks following release proving especially fatal. Extended-release naltrexone (XR-NTX) is the most widely-accepted, evidence-based OUD pharmacotherapy in criminal justice settings, and ensures approximately 30 days of protection from opioid overdose. The high cost of XR-NTX serves as a barrier to uptake by many prison/jail systems; however, the cost of the medication should not be viewed in isolation. Prison/jail healthcare budgets are ultimately determined by policymakers, and the benefits/cost-offsets associated with effective OUD treatment will directly and indirectly affect their overall budgets, and society as a whole.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p id="Par2">This protocol describes a study funded by the National Institute of Drug Abuse (NIDA) to: evaluate changes in healthcare utilization, health-related quality-of-life, and other resources associated with different strategies of XR-NTX delivery to persons with OUD being released from incarceration; and estimate the relative “value” of each strategy. Data from two ongoing, publicly-funded, randomized-controlled trials will be used to evaluate these questions. In Study A, (XR-NTX Before vs. After Reentry), participants are randomized to receive their first XR-NTX dose before release, or at a nearby program post-release. In Study B, (enhanced XR-NTX vs. XR-NTX), both arms receive XR-NTX prior to release; the enhanced arm receives mobile medical (place of residence) XR-NTX treatment post-release, and the XR-NTX arm receives referral to a community treatment program post-release. The economic data collection instruments required to evaluate outcomes of interest were incorporated into both studies from baseline. Moreover, because the same instruments are being used in both trials on comparable populations, we have the opportunity to not only assess differences in outcomes between study arms within each trial, but also to merge the data sets and test for differences across trials.</p>
                </sec>
                <sec>
                  <title>Discussion</title>
                  <p id="Par3">Initiating XR-NTX for OUD prior to release from incarceration may improve patient health and well-being, while also producing downstream cost-offsets. This study offers the unique opportunity to assess the effectiveness and cost-effectiveness of multiple strategies, according to different stakeholder perspectives.</p>
                </sec>
              </abstract>
              <kwd-group xml:lang="en">
                <title>Keywords</title>
                <kwd>Opioid use disorder</kwd>
                <kwd>Justice involved persons</kwd>
                <kwd>Extended-release naltrexone</kwd>
                <kwd>Healthcare utilization</kwd>
                <kwd>Health-related quality-of-life</kwd>
                <kwd>Cost-effectiveness</kwd>
              </kwd-group>
              <funding-group>
                <award-group>
                  <funding-source>
                    <institution-wrap>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id>
                      <institution>National Institute on Drug Abuse</institution>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01DA046721</award-id>
                  <award-id>R01DA040636</award-id>
                  <award-id>P30DA040500</award-id>
                  <principal-award-recipient>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>Sean M.</given-names>
                    </name>
                    <name>
                      <surname>Gordon</surname>
                      <given-names>Michael S.</given-names>
                    </name>
                  </principal-award-recipient>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>issue-copyright-statement</meta-name>
                  <meta-value>© The Author(s) 2020</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec id="Sec1">
              <title>Background</title>
              <p id="Par20">The US is in the middle of an opioid epidemic, with an estimated 2.1 million US persons (aged 12 years and older) experiencing opioid use disorder in 2017 [<xref ref-type="bibr" rid="CR1">1</xref>], and 47,600 people dying from a drug overdose attributed to opioids, which represents an increase in the age-adjusted rate of almost 400% since 2000 [<xref ref-type="bibr" rid="CR2">2</xref>]. Opioid misuse has been associated with violent behavior and increased criminal activity [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR7">7</xref>]; concomitantly, approximately 50% of inmates suffer from a drug use disorder, versus only 2% of the general U.S. population [<xref ref-type="bibr" rid="CR8">8</xref>]. Individuals being released from incarceration face many unique challenges to remaining abstinent from opioids [<xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR11">11</xref>]. For example, persons who were incarcerated are faced with stigma, they must secure housing and employment, and they must abide by other supervision requirements associated with their release, all while trying to re-affiliate themselves with family and friends. These challenges, combined with the fact that, while incarcerated, persons with a history of opioid use disorder typically do not lose their opioid cravings, but may lose their tolerance, result in high rates of opioid relapse, overdose, and overdose death following release from incarceration [<xref ref-type="bibr" rid="CR12">12</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. In fact, opioid-overdose is the leading cause of death among persons who were incarcerated, with the first 2 weeks following release from incarceration proving especially fatal [<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref>].</p>
              <p id="Par21">Methadone, buprenorphine, or naltrexone pharmacotherapy is recommended as the first-line treatment for opioid use disorder [<xref ref-type="bibr" rid="CR17">17</xref>]. Methadone and buprenorphine are effective, and cost-effective pharmacotherapies for opioid use disorder [<xref ref-type="bibr" rid="CR7">7</xref>], and have been shown to be associated with increased rates of entry to community-based treatment [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>], treatment retention [<xref ref-type="bibr" rid="CR20">20</xref>–<xref ref-type="bibr" rid="CR22">22</xref>], and opioid abstinence [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], when provided to persons who are incarcerated, just prior-to or immediately-following release; however, these medications are often unavailable to justice-involved populations [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. According to a 2003 nationwide survey, only 1% of persons who were incarcerated and reported regular opioid use received methadone or buprenorphine treatment [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. A more recent survey of a convenience sample of 18 jails and 12 prisons associated with an ongoing research study, revealed that one-third of the facilities were offering opioid use disorder pharmacotherapy to persons who entered incarceration on medication, and only one offered pharmacotherapy to persons who did not enter on a medication [<xref ref-type="bibr" rid="CR26">26</xref>]. Two of the most commonly cited reasons for this lack of support for opioid agonist therapy were a preference for drug-free detoxification, and security concerns about providing the medications within the jail or prison [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR26">26</xref>]. The security concerns likely stem from the fact that buprenorphine and methadone are narcotics, and therefore the incentive to misuse or divert the medications, exists. Furthermore, both methadone and buprenorphine have added legal barriers. Methadone can only be prescribed through a certified opioid treatment program, while buprenorphine requires the provider to obtain a waiver under the Drug Addiction Treatment Act of 2000 [<xref ref-type="bibr" rid="CR27">27</xref>]. Moreover, the majority of institutions do not even refer individuals to clinics/providers offering pharmacotherapy, upon release [<xref ref-type="bibr" rid="CR23">23</xref>], and, among justice-involved persons who are referred to specialty treatment for opioid use disorder, findings suggest that less than 5% receive methadone or buprenorphine, compared to 41% of those referred from other sources [<xref ref-type="bibr" rid="CR28">28</xref>].</p>
              <p id="Par22">Naltrexone has some advantages as an opioid use disorder pharmacotherapy that make it more attractive to many prison/jail systems; it is a full opioid antagonist and therefore is non-narcotic and non-addictive [<xref ref-type="bibr" rid="CR29">29</xref>], it is relatively non-stigmatized [<xref ref-type="bibr" rid="CR30">30</xref>], and it can be prescribed by any healthcare provider licensed to prescribe medications [<xref ref-type="bibr" rid="CR29">29</xref>]. Additionally, the extended-release naltrexone (XR-NTX) injection provides persons being released from incarceration with approximately 30 days of protection from opioid overdose. However, the high price of XR-NTX may serve as barrier to access. The upper-bound, wholesale acquisition cost of one XR-NTX injection is $1309 [<xref ref-type="bibr" rid="CR31">31</xref>], while the lower-end cost to the Department of Veterans Affairs is $897 [<xref ref-type="bibr" rid="CR32">32</xref>]. To put the price of XR-NTX in context, at the time of the aforementioned national survey of prison systems [<xref ref-type="bibr" rid="CR23">23</xref>], the wholesale acquisition cost of name-brand buprenorphine-naloxone (Suboxone<sup>®</sup>) was only $200 per month [<xref ref-type="bibr" rid="CR33">33</xref>], and 18% of prison systems indicated the cost of buprenorphine was prohibitive.</p>
              <p id="Par23">It is critical that the policymakers who are ultimately setting prison/jail healthcare budgets [<xref ref-type="bibr" rid="CR34">34</xref>], and making decisions on behalf of taxpayers and society as a whole, do not view the cost of opioid use disorder therapy for the high-risk population of persons being released from incarceration, in isolation. This protocol describes a study funded by the National Institute of Drug Abuse (NIDA), which will use data from two ongoing randomized-controlled trials assessing different models of XR-NTX treatment among persons being released from incarceration, to evaluate the following questions: (a) what are the costs to the correctional health system of implementing and running each XR-NTX program; (b) do the programs produce downstream savings for state governments from reduced utilization of high-cost healthcare services, such as emergency department (ED) visits and inpatient stays [<xref ref-type="bibr" rid="CR7">7</xref>], criminal activity [<xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR7">7</xref>], and recidivism [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]; (c) do the programs produce additional benefits for participants and society, such as enhanced quality of life, reduced risk of overdose/overdose death [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], and improved workplace or school productivity [<xref ref-type="bibr" rid="CR7">7</xref>]; and (d) under what circumstances are the programs cost-effective from the perspectives of state policymakers, and society.</p>
            </sec>
            <sec id="Sec2">
              <title>Methods/Design</title>
              <sec id="Sec3">
                <title>Overview</title>
                <p id="Par24">The economic analyses will follow recommendations of the Second Panel on Cost Effectiveness in Health and Medicine [<xref ref-type="bibr" rid="CR37">37</xref>], Glick et al. [<xref ref-type="bibr" rid="CR38">38</xref>], and Drummond [<xref ref-type="bibr" rid="CR39">39</xref>], Data from two ongoing, publicly-funded, randomized controlled effectiveness trials in which XR-NTX is being evaluated among persons being released from incarceration who have an opioid use disorder, will be used to achieve the study objectives. In Study A, titled “Extended Release Injectable Naltrexone Before vs. After Release: A Randomized Trial of Opioid Addicted Prisoners” (Woody, PI; PCORI-1409-21688; XR-NTX Before vs. After Reentry), those randomized to the pre-reentry XR-NTX arm get their first dose prior to reentry and a referral to post-reentry treatment; the post-reentry XR-NTX arm is referred to a local provider to receive their first dose following reentry. In Study B, titled “Long-Acting Naltrexone for Pre-Release Prisoners: A Randomized Trial of Mobile Treatment” (Gordon, PI; R01DA040636; enhanced XR-NTX vs. XR-NTX), both arms receive XR-NTX prior to reentry; following reentry, the enhanced arm receives monthly mobile medical XR-NTX treatment at the participant’s place of residence, while the XR-NTX arm receives referral to a community opioid treatment program. Specifically, we will evaluate whether enhanced XR-NTX with mobile medical treatment for opioid use disorder among persons being released from incarceration is associated with more primary and behavioral healthcare services, but fewer emergency and inpatient services; enhanced participant wellbeing; and economic viability from state policymaker and societal perspectives, compared to (a) XR-NTX prior to reentry plus referral to post-reentry treatment, and (b) referral to post-reentry treatment only. We will also calculate the costs of implementing and continuously managing each pre-release XR-NTX intervention from the perspective of the correctional health system.</p>
                <p id="Par25">We chose to focus on the state policymaker and societal perspectives, as opposed to the healthcare sector perspective for example, because they are particularly relevant for opioid use disorder interventions in this population. However, given the information we are collecting, it will be possible to examine value from other perspectives, if necessary. The state policymaker perspective is crucial to informing resource allocation decisions on behalf of the public, who is primarily responsible for funding prison/jail interventions for substance use disorders, subsequent therapy, and other healthcare for formerly incarcerated persons, as well as the direct costs associated with recidivism. In our prior study of community-dwelling, justice-involved persons with an opioid use disorder, 98% were either on Medicaid or uninsured [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. The state policymaker perspective will include all study and non-study healthcare costs (e.g., opioid and other substance use disorder therapy; inpatient, outpatient, and ED services; behavioral therapy) paid by Medicaid, and all direct costs to the criminal justice system. In addition to the costs included in the state policymaker perspective, the societal perspective accounts for many of the indirect costs associated with opioid misuse, regardless of who shares the burden [<xref ref-type="bibr" rid="CR37">37</xref>]; thus, it will also include indirect costs associated with criminal activity (e.g., property damage, pain and suffering, etc.), reduced workplace and school productivity, and those associated with participant time and travel to receive treatment. Not accounting for these indirect costs and the potential value offsets can undermine the true benefit of an intervention. Participant-level costs will be estimated using the resource costing method, which entails weighting each resource unit consumed by a pre-determined unit cost, and summing the values over the relevant time period [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p>
              </sec>
              <sec id="Sec4">
                <title>Overview of study A (Woody, PI): XR-NTX before vs. after reentry</title>
                <p id="Par26">This clinical trial is enrolling 200 persons being released from incarceration who met study admission criteria and expressed interest in XR-NTX treatment. Participants were stratified by sex and sentence requirements for post-reentry criminal justice system contacts (i.e. whether or not required to meet with probation/parole officer) and randomized 1:1 to (a) XR-NTX prior to reentry plus referral to post-reentry treatment, and (b) referral to post-reentry treatment only. Those assigned to the pre-reentry XR-NTX arm receive XR-NTX before reentry with the offer of 3 additional doses of XR-NTX delivered at a community opioid treatment program after reentry. Those assigned to the post-reentry arm are given an appointment to be seen at a community opioid treatment program where they can be admitted within 1–3 days of reentry to receive their first dose of XR-NTX, with the offer of 3 additional doses at the community treatment center. The primary outcome is relapse during the first 3 months after reentry.</p>
              </sec>
              <sec id="Sec5">
                <title>Overview of study B (Gordon, PI): enhanced XR-NTX with mobile medical treatment vs. XR-NTX</title>
                <p id="Par27">This clinical trial is enrolling 180 prisoners who meet study admission criteria and express interest in XR-NTX treatment. Participants are being stratified by sex and randomized 1:1 to enhanced XR-NTX or XR-NTX. Those assigned to enhanced XR-NTX receive one injection of XR-NTX in prison followed by 6 monthly injections post-release at the participant’s place of residence via mobile medical treatment. Those assigned to XR-NTX receive one injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program. The primary outcomes being evaluated are XR-NTX treatment adherence (number of injections received), opioid abstinence, criminal activity (self-report days), re-arrest and re-incarceration (official records), and HIV risk-behaviors (self-report).</p>
              </sec>
              <sec id="Sec6">
                <title>Inclusion/exclusion criteria for studies A and B</title>
                <p id="Par28">The inclusion criteria for Studies A and B include: adult males or females who are incarcerated, and eligible for release within 30–60 days; history of DSM-V opioid use disorder; interested in, and suitable for XR-NTX treatment as determined by medical evaluation; detoxified and able to pass a naloxone challenge; able to provide informed consent; willingness to enroll in XR-NTX treatment in prison [not currently in or planning to pursue agonist (methadone, buprenorphine) treatment at release]; and planning to live in the study area during the study period. Potential participants who meet any of the following will be excluded: renal disorder; active medical illness that may make participation hazardous (e.g., unstable diabetes, heart disease); untreated psychiatric disorder that may make participation hazardous (e.g., untreated psychosis, bipolar disorder with mania); history of allergic reaction to XR-NTX; current chronic pain diagnosis for which opioids are prescribed; creatinine above normal limits; pregnancy (for women); breast-feeding (for women); suicidal ideation (within the past 6-months); Body Mass Index (BMI) &gt; 40; or unadjudicated charges that may result in transfer to another facility or additional prison time.</p>
              </sec>
            </sec>
            <sec id="Sec7">
              <title>Measures</title>
              <p id="Par29">The Participant Data Collection Schedule (Table <xref rid="Tab1" ref-type="table">1</xref>) contains a list of measures relevant to this project and when they will be collected from participants for each study. Additionally, we will administer the Drug Abuse Treatment Cost Analysis Program (DATCAP) instrument at the program level for each trial, once the programs have reached a steady state. Self-report instruments of healthcare resource utilization and criminal activity will utilize recall periods anchored at the last assessment, in order to capture information that would be missed by standard 30-day recall periods, in the event a participant fails to attend a study visit.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Data Collection Schedule</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="4"/><th align="left" colspan="16">Month</th></tr><tr><th align="left" colspan="2">0</th><th align="left" colspan="2">1</th><th align="left" colspan="2">2</th><th align="left" colspan="2">3</th><th align="left" colspan="2">4</th><th align="left" colspan="2">5</th><th align="left" colspan="2">6</th><th align="left">7</th><th align="left">12</th></tr><tr><th align="left" colspan="16">Study</th></tr><tr><th align="left">A</th><th align="left">B</th><th align="left">A</th><th align="left">B</th><th align="left">A</th><th align="left">B</th><th align="left">A</th><th align="left">B</th><th align="left">A</th><th align="left">B</th><th align="left">A</th><th align="left">B</th><th align="left">A</th><th align="left">B</th><th align="left">B</th><th align="left">B</th></tr></thead><tbody><tr><td align="left">Non-study Medical and Other Services form (self-report)</td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td></tr><tr><td align="left">Health-related quality of life-EuroQol-5D (self-report)</td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td></tr><tr><td align="left">Arrests and incarcerations (criminal record)</td><td align="left" colspan="16">Ongoing</td></tr><tr><td align="left">Criminal and Legal Activities Form (self-report)</td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td></tr><tr><td align="left">Opioid use (biochemical)</td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td></tr><tr><td align="left">Opioid use (self-report)</td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td></tr><tr><td align="left">Addiction Severity Index</td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"/><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td><td align="left"><bold>√</bold></td></tr></tbody></table></table-wrap></p>
              <p id="Par30">The <bold>DATCAP</bold> is a standardized, customizable tool that can be used to estimate the costs of programs in various settings, and allows for the estimation of both <italic>accounting</italic> and <italic>economic costs</italic> [<xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>]. <italic>Accounting costs</italic> are defined as “the actual expenditures and depreciation of all resources used by the treatment program.” [<xref ref-type="bibr" rid="CR43">43</xref>] <italic>Economic costs</italic> are considered to be <italic>accounting costs</italic>, plus the value of any resources used by the program that are either subsidized or donated. Including <italic>economic costs</italic> increases generalizability of the estimates, since it is unlikely that resources will be subsidized or donated in all instances.</p>
              <p id="Par31"><bold>Non-study Medical and Other Services (NMOS).</bold> The use of non-study medical services (e.g., inpatient, outpatient, and ED services, and non-study medications) is being assessed using Timeline Follow-Back (TLFB) [<xref ref-type="bibr" rid="CR45">45</xref>] methodology via the NMOS form. The use of other non-study resources (e.g., workplace productivity, travel time to medical care) will also be self-reported and collected by the NMOS form. The validity of self-reported data on healthcare utilization is well established over recall periods similar to those in our study [<xref ref-type="bibr" rid="CR46">46</xref>–<xref ref-type="bibr" rid="CR49">49</xref>]. The NMOS form has been successfully used by our team in prior economic evaluation studies [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR50">50</xref>–<xref ref-type="bibr" rid="CR53">53</xref>], and is ideal for capturing the utilization of all relevant non-study resources for this project.</p>
              <p id="Par32"><bold>Health-related quality of life (HRQoL)</bold> is measured by the EuroQol 5D, 3 level (EQ-5D-3L) instrument [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR56">56</xref>]. The EQ-5D is the most widely-used generic, preference-based HRQoL instrument [<xref ref-type="bibr" rid="CR57">57</xref>]. The EQ-5D-3L measures HRQoL across 5 dimensions: <italic>mobility</italic>, <italic>self</italic>-<italic>care</italic>, <italic>usual activities</italic>, <italic>pain/discomfort</italic>, and <italic>anxiety/depression</italic>, and consists of 3 levels for each domain: <italic>no problems</italic>, <italic>some problems</italic>, and <italic>extreme problems</italic>. The EQ-5D-3L is capable of generating a single health utility index value based on the respondent’s scores for each domain. The health-utility value represents the general US population’s preference for the respondent’s current health state. The health-utility value produced by the EQ-5D-3L can range from − 0.594 to 1, where 0 represents death, 1 represents perfect health, and values below 0 represent health states perceived to be worse than death. The index value can then be used to calculate quality-adjusted life-years (QALYs), as our team, and others have done in similar studies [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR52">52</xref>].</p>
              <p id="Par33"><bold>Re-arrest and re-incarceration</bold> information will be obtained using official criminal records. These data will include type (e.g., charges involved), number of arrests, convictions, incarcerations, and the length of time of each imposed disciplinary period. We anticipate that most recidivism will be captured by the official records described above; however, we are supplementing these records with self-reported data from the <bold>Criminal and Legal Activities Form (CLAF)</bold> to ensure comprehensive measurement of criminal justice resources utilized, including those relevant to the societal perspective that are not captured in criminal records. The CLAF uses TLFB methodology to capture: days of criminal activity; average number of crimes per day on days when illegal activity occurred; days incarcerated; specific crimes committed; whether the participant was charged with or convicted of the crime; visits to the individual’s parole/probation officer; and parole/probation violations. The self-report method for collecting data on criminal activity has acceptable validity and reliability [<xref ref-type="bibr" rid="CR58">58</xref>], including among individuals with a substance use disorder, and those on probation or parole [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. The CLAF has been successfully used by our team in prior studies to value criminal activity and criminal justice resources from various perspectives [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR50">50</xref>–<xref ref-type="bibr" rid="CR52">52</xref>], and we recently developed recommendations on how to use different measures of criminal activity in economic evaluations [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
              <p id="Par34"><bold>Opioid use</bold> is being assessed biochemically via urine or saliva drug tests prior to administration of XR-NTX in prison and the community, and supplemented with self-reported use of opioids (and alcohol and other drugs), measured using the TLFB method.</p>
              <p id="Par35"><bold>Addiction Severity Index (ASI) [</bold><xref ref-type="bibr" rid="CR62">62</xref><bold>] with TLFB</bold>. The ASI is being used to assesses the severity of drug and alcohol use disorders, and the effects of opioid use on the participant’s psychiatric, legal, medical, employment, and family functioning. A composite score can be created for each of these seven areas that provides a valid and reliable measure of the participant’s status. The composite scores will be evaluated for potential use as covariates in our empirical models. We will also utilize the ASI data on substance use frequency and criminal activity to supplement biochemical opioid use and criminal record data.</p>
              <p id="Par36"><bold>Opioid use severity.</bold> We will use the DSM-V opioid-related-disorder classification [<xref ref-type="bibr" rid="CR63">63</xref>], collected as part of the inclusion/exclusion criteria, to assess opioid use severity (mild, moderate, severe) at baseline. Opioid use severity will be evaluated for potential use as a covariate in our empirical models.</p>
              <p id="Par37"><bold>Unit costs.</bold> Sources of our unit cost estimates are listed in Table <xref rid="Tab2" ref-type="table">2</xref>. The cost of the study-provided therapy will be based on the resources utilized to deliver the 380 mg injection of XR-NTX, which includes the dispensing fee that will be calculated using the DATCAP. For the state policymaker perspective, we will obtain and use the Transformed Medicaid Statistical Information System (T-MSIS) data from the Centers for Medicare and Medicaid Services (CMS), to calculate the cost of all medications and healthcare resources [<xref ref-type="bibr" rid="CR64">64</xref>]. The T-MSIS data contains the following information from all 50 states, Washington DC, and two US territories (Virgin Islands and Puerto Rico): enhanced information about beneficiary eligibility, beneficiary and provider enrollment service utilization, claims and managed care data, and expenditure data for Medicaid and CHIP. The costs from the T-MSIS database will be calculated for individuals with a DSM-V diagnosed opioid use disorder who are in an age-range reflective of our final study samples.<table-wrap id="Tab2"><label>Table 2</label><caption><p>Unit Cost Sources for Economic Evaluation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Measure</th><th align="left">Utilization data source</th><th align="left">Unit cost source–policymaker perspective</th><th align="left">Unit cost source–societal perspective</th></tr></thead><tbody><tr><td align="left" colspan="4"><bold><italic>Substance use disorder therapy</italic></bold></td></tr><tr><td align="left">XR-NTX</td><td align="left">Study documents &amp; NMOS</td><td align="left">T-MSIS + dispensing fee estimated via DATCAP</td><td align="left">FSS + dispensing fee estimated via DATCAP</td></tr><tr><td align="left">Methadone and buprenorphine</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">FSS</td></tr><tr><td align="left">Behavioral therapy</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">Medicare FFS</td></tr><tr><td align="left">Inpatient detoxification</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">Medicare FFS</td></tr><tr><td align="left">Residential treatment</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">Medicare FFS</td></tr><tr><td align="left" colspan="4"><bold><italic>Other healthcare services</italic></bold></td></tr><tr><td align="left">Hospital stays</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">Medicare FFS</td></tr><tr><td align="left">Outpatient visits</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">Medicare FFS</td></tr><tr><td align="left">Emergency department visits</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">Medicare FFS</td></tr><tr><td align="left">Mental health visits</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">Medicare FFS</td></tr><tr><td align="left">Other prescriptions</td><td align="left">NMOS</td><td align="left">T-MSIS</td><td align="left">FSS</td></tr><tr><td align="left" colspan="4"><bold><italic>Criminal justice activities</italic></bold></td></tr><tr><td align="left">Specific crimes</td><td align="left">Criminal records &amp; CLAF</td><td align="left">McCollister et al. (2010): direct costs</td><td align="left">McCollister et al. (2010): societal costs</td></tr><tr><td align="left">Probation visits</td><td align="left">CLAF</td><td align="left">BLS</td><td align="left">BLS</td></tr><tr><td align="left" colspan="4"><bold><italic>Other resources</italic></bold></td></tr><tr><td align="left">Work</td><td align="left">NMOS</td><td align="left">N/A</td><td align="left">Self-reported wages &amp; hours worked</td></tr><tr><td align="left">Education</td><td align="left">NMOS</td><td align="left">N/A</td><td align="left">Self-reported time in school &amp; Card (1999) estimates</td></tr><tr><td align="left">Participant time</td><td align="left">NMOS</td><td align="left">N/A</td><td align="left">Self-reported or federal minimum wage</td></tr><tr><td align="left">Participant travel</td><td align="left">Site visit</td><td align="left">N/A</td><td align="left">Area public transportation fees &amp; IRS mileage rates</td></tr></tbody></table><table-wrap-foot><p><italic>NMOS</italic> Non-study Medical and Other Services form, <italic>T-MSIS</italic> Transformed Medicaid Statistical Information System, <italic>DATCAP</italic> Drug Abuse Treatment Cost Analysis Program instrument, <italic>FSS</italic> Department of Veterans Affairs Federal Supply Schedule, <italic>CLAF</italic> Criminal and Legal Activities Form, <italic>Medicare FFS</italic> Medicare fee-for-service</p></table-wrap-foot></table-wrap></p>
              <p id="Par38">The societal perspective should account for the “actual value” of all resources associated with the intervention [<xref ref-type="bibr" rid="CR37">37</xref>]. Thus, Medicare fee-for-service payments will be used to value healthcare resources utilized from the societal perspective, as these payments are designed to reimburse providers for the resources that would be used to treat a typical patient with a given condition and are adjusted for relevant factors that are unique to the patient or provider [<xref ref-type="bibr" rid="CR65">65</xref>], as opposed to also including a component for profit and risk adjustment [<xref ref-type="bibr" rid="CR37">37</xref>]. Similarly, the US Department of Veterans Affairs Federal Supply Schedule will be used to value all medications in the societal perspective, as recommended by the Second Panel on Cost Effectiveness in Health and Medicine [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
              <p id="Par39">Unit cost estimates developed by McCollister et al. [<xref ref-type="bibr" rid="CR66">66</xref>] will be used to value the resources associated with specific crimes committed. These costs include the direct costs to the criminal justice system (e.g., police-protection, legal and adjudication, and corrections costs), which will be used to inform the state policymaker perspective, as well as societal costs that combine the criminal-justice-system costs with those incurred by victims, both tangible (e.g., medical, property damage or loss, etc.) and intangible (i.e., pain and suffering). Probation officers’ time will be valued according to the mean annual salary and benefit rate reported by the Bureau of Labor Statistics (BLS) [<xref ref-type="bibr" rid="CR67">67</xref>].</p>
              <p id="Par40">The benefits of work-force participation will be estimated according to the participant’s self-reported wage rate and time spent working. Educational activities will be valued according to self-reported time in school and the estimated return for a year of schooling in the United States [<xref ref-type="bibr" rid="CR68">68</xref>], applied to the lifetime earnings for individuals in the relevant age range [<xref ref-type="bibr" rid="CR69">69</xref>]. Participant time costs will be calculated using the self-reported amount of time spent on healthcare-related activities (including travel) and the estimated school or workforce value of the participant’s time [<xref ref-type="bibr" rid="CR37">37</xref>]. We will use the federal minimum wage to value the time for individuals who are unemployed. If we are able to obtain person-level travel information, including distance traveled and mode of transportation, we will calculate the direct costs of travel accordingly. The cost of public transportation in the area will be used to value the out-of-pocket transportation costs for those using public transit, and IRS standard mileage rates will be used to value transportation costs for those with private transportation. Otherwise, participant transportation costs will be valued according to the average distance traveled by participants, weighted by the proportion who used public transportation versus private transportation, and their respective costs, which will be provided by study staff during site visits.</p>
            </sec>
            <sec id="Sec8">
              <title>Outcomes</title>
              <p id="Par41">The study is comprised of four components, each with its own outcome(s), that culminate in cost-effectiveness analyses. First, we will estimate the cost to the correctional health system of implementing and running each XR-NTX program. Second, we will evaluate differences in the utilization of healthcare services associated with opioid use, across the different arms. Specifically, we will evaluate differences in number of ED, inpatient, primary care, and behavioral healthcare visits. Third, we will evaluate differences in QALYs gained across arms. Finally, we will conduct cost-effectiveness analyses, the primary outcome for which will be the incremental cost-effectiveness ratio (ICER). An ICER is calculated as the incremental cost of a chosen strategy relative to another, divided by the incremental effectiveness of the strategy of interest relative to the other. We will use two measures of effectiveness, one economic, and one clinical. The economic measure of effectiveness will be the QALY. The QALY is an ideal denominator for a cost-effectiveness analysis, as it provides a common measure of effectiveness that permits comparisons across disorders, diseases, and interventions. In addition, generally accepted thresholds for defining value have been established for QALYs, unlike clinical measures [<xref ref-type="bibr" rid="CR70">70</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. The clinical measure of effectiveness will be <italic>Abstinent Years</italic>, the proportion of the year the individual was abstinent from opioids. Time abstinent is an important measure of effectiveness for clinical stakeholders, and calculating cost-per-<italic>Abstinent</italic>-<italic>Year</italic> enables comparisons with existing economic evaluations that have utilized similar effectiveness measures, especially those that have relied solely on time abstinent measures [<xref ref-type="bibr" rid="CR7">7</xref>].</p>
            </sec>
            <sec id="Sec9">
              <title>Analysis</title>
              <p id="Par42">The first step of estimating the cost to the correctional health system of implementing and running each XR-NTX program will be to tailor the DATCAP to each setting. Next, we will conduct focused interviews of administrators and staff associated with each treatment strategy across Studies A and B, to ensure that all resources required to implement and continuously manage them, are being captured. The implementation cost will include one-time fixed costs associated with starting the intervention, as well as all monthly fixed and variable costs associated with resources that will be required to manage each treatment strategy on an ongoing basis. Through our interviews, we will estimate the number of patients that could be treated using each strategy on a daily basis, given the current resources, and subsequently calculate the mean costs. The one-time fixed costs associated with starting each strategy will be reported separately; that is, they will not be included in the subsequent economic analyses since they become negligible over time. Research-specific costs will be excluded.</p>
              <p id="Par43">All participant-level data will be analyzed under an intent-to-treat principle, and all analyses will be conducted using a multivariable Generalized Linear Mixed Model (GLMM). The GLMM is an extension of the GLM that allows for the inclusion of random effects. The multivariable aspect of the model is crucial both for the within study comparisons of treatment arms, and the between study comparison of treatment arms, as it allows for the control of factors that are unbalanced between arms because they were not accounted for in the randomization process or may have become unbalanced over time due to loss to follow-up. The GLMM allows one to choose the most appropriate mean and variance functions according to the observed data, and uses all available data for each participant, regardless of whether or not it is complete, making it an ideal statistical procedure for intent-to-treat approaches [<xref ref-type="bibr" rid="CR38">38</xref>]. Given the differences in mechanisms to generate data, separate multivariable GLMMs will be estimated to predict the mean value for each resource and outcome, at each time period, by study arm. The method of recycled predictions will be used to obtain the final predicted mean values [<xref ref-type="bibr" rid="CR38">38</xref>]. To account for sampling uncertainty in point estimates, the p-values and standard errors will be estimated using nonparametric bootstrapping techniques within the multivariable framework. All monetary values will be adjusted for inflation.</p>
              <p id="Par44">For Study A (Woody, PI) we will model the person period for each 3-month period where detailed assessments are given to participants (i.e., months 3 and 6). For Study B (Gordon, PI) we will model the person period monthly for the first 7 months and the 5-month follow-up period. By analyzing the relevant person-period for each study, according to when detailed assessments are given to participants, we are able to utilize all observed data from each participant, while accurately identifying and dealing with missing data, and, in addition to the potential confounders discussed above, controlling for differences between arms over time [<xref ref-type="bibr" rid="CR38">38</xref>.] Next, we will aggregate the monthly values from Study B to align with the 3 and 6 month observation periods of Study B, merge the two datasets, and model the 3- and 6-month person periods.</p>
              <p id="Par45">To better understand the differences in healthcare resource utilization across treatment strategies, we will test for differences in the predicted number of ED, inpatient, primary care, and behavioral healthcare visits between study arms both within- and across-studies over the course of the intervention and follow-up periods, using the methods described above. Similarly, to estimate whether health-related quality-of-life varies across treatment strategies, the predicted health utility index values obtained from the GLMM will be used to estimate QALYs gained using the area under the curve methodology [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR72">72</xref>], which will then be tested in a similar fashion.</p>
              <p id="Par46">Healthcare services utilized will then be weighted by their respective unit costs and predicted values will be generated. The predicted mean costs for each resource category will be summed and tested according to the relevant perspective, and incorporated into a comprehensive cost-effectiveness analysis along with the predicted outcomes and the average ongoing management costs of each strategy. Four ICERs will be constructed for Study A (Woody, PI), Study B (Gordon, PI), and the combined analysis; i.e., an ICER for each effectiveness measure (QALYs and <italic>Abstinent Years</italic>) and each perspective (state-policymaker and societal). ICER confidence intervals will be estimated using nonparametric bootstrapping techniques within the multivariable framework. Parametric methods based on parameters obtained from bootstrapping will be used to estimate acceptability curves, which illustrate the probability that the intervention is a good value for different willingness-to-pay thresholds (i.e., cost-per-QALY and cost-per-<italic>Abstinent</italic>-<italic>Year</italic>). ICERs will be calculated and acceptability curves will be constructed regardless of the statistical significance for individual cost and effectiveness differences, as the power to detect a difference in costs and effects jointly exceeds the power to do so individually [<xref ref-type="bibr" rid="CR38">38</xref>].</p>
              <p id="Par47">Sensitivity analyses will be performed to account for uncertainty in assumptions and parameter estimates applied in the analysis [<xref ref-type="bibr" rid="CR37">37</xref>]. For example, values estimated using the relatively robust and efficient GLMM regression will be compared to those estimated using the more transparent ordinary least squares regression, as well as to the unadjusted mean values. We will also vary the prices of resources, especially the price of the XR-NTX injection, as our prior analyses revealed sensitivity in the cost-effectiveness outcomes around the XR-NTX price [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</p>
            </sec>
            <sec id="Sec10">
              <title>Timeline</title>
              <p id="Par48">This is a 4 year study, designed to coincide with the timelines of Study A (Woody, PI) and B (Gordon, PI); we are currently in the beginning of Year 2. The first step of the analysis plan, estimating the cost to the correctional health system of implementing and running each XR-NTX program, is in process for both studies. Study A was recently completed and is in the process of conducting analyses of their primary outcomes; thus, we will be receiving the trial data soon to begin the within-study analyses of healthcare resource utilization, QALYs, and cost-effectiveness. Study B (Gordon, PI) is in Year 3 of 5 and is nearing completion of recruitment/randomization. We anticipate that the follow-up assessments for Study B will be complete late in Year 3 of this project.</p>
            </sec>
            <sec id="Sec11">
              <title>Discussion</title>
              <p id="Par49">A notable treatment gap persists among the high-risk population of justice-involved persons with opioid use disorder. Persons just released from incarceration are at a particularly high risk for opioid overdose and overdose deaths. Evidence suggests that evidence-based pharmacotherapy just prior to release is associated with positive outcomes; unfortunately, barriers to access of these opioid use disorder treatments exist for this population. XR-NTX has some characteristics that make it relatively attractive to many prison/jail systems, and it provides protection from opioid overdose for approximately 30 days; however, the high cost of the medication represents yet another barrier to access. It is critical that the policymakers who are ultimately setting prison/jail healthcare budgets [<xref ref-type="bibr" rid="CR34">34</xref>], and making decisions on behalf of taxpayers and society as a whole, do not view the cost of opioid use disorder therapy for this high-risk population, in isolation. This protocol describes an innovative study that will fill a critical knowledge-gap in the literature and inform the “real-world” resource allocation decisions faced by policymakers and correctional health systems. We will analyze data from two randomized clinical trials, independently and together, to evaluate whether XR-NTX treatment is associated with expected changes in the utilization of healthcare services, enhanced patient wellbeing, and economic viability from state policymaker and societal perspectives among the previously-unstudied, high-risk population of persons with opioid use disorder who are being released from incarceration. We will also have the unprecedented opportunity to measure health-related quality-of-life (HRQoL) among persons with opioid use disorder who were incarcerated, prior to their release, and then track changes in their HRQoL following their release and subsequent engagement with treatment.</p>
            </sec>
            <sec id="Sec12">
              <title>Limitations</title>
              <p id="Par50">The generalizability of our findings may be limited to justice-involved persons with an opioid use disorder; however, we believe this study is highly significant due to (a) the size of the US criminal justice population, (b) the rate of drug use disorders among this population, and (c) the concomitant personal and public health costs. The study relies heavily on self-reported data; however, the validity of self-reported data on healthcare use is well established over recall periods, and among populations, similar to those in our study, and our team has successfully completed numerous economic evaluations using the same instruments proposed here. Although EHR or administrative claims datasets are likely to capture a more detailed set of services than self-report forms, these data are generally limited in their ability to capture and value all relevant healthcare resource utilization among trial participants. The study sample is likely to consist of individuals who lack health insurance; for example, in our prior study on community-dwelling, criminal-justice-involved persons with an opioid use disorder, 29% of participants were uninsured [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>]. The data for those who are insured would likely require access to a number of different administrative systems, which would not be feasible. Even if we could access all systems, only a limited subsample may agree to release their health insurance records [<xref ref-type="bibr" rid="CR73">73</xref>]. Also, the use of claims data limits the evaluation to those healthcare items that are covered, and periods when the individual was covered; moreover, the monetary values in these data often reflect reported charges, as opposed to costs, and the conversion of charges to costs can be inaccurate [<xref ref-type="bibr" rid="CR74">74</xref>].</p>
            </sec>
            <sec id="Sec13">
              <title>Conclusion</title>
              <p id="Par51">The opioid epidemic continues to escalate, and persons being released from incarceration are at especially high risk for opioid relapse, overdose, and overdose death immediately following release. Furthermore, this population faces a number of significant barriers to obtaining evidence-based therapy. Currently, XR-NTX has the highest rate of acceptance in criminal justice settings [<xref ref-type="bibr" rid="CR75">75</xref>], yet its relatively high cost serves as a potential barrier to access if viewed myopically. This study is uniquely positioned to deepen our understanding of the impact that XR-NTX treatment for opioid use disorder could have in the criminal justice system, the spillover effects to society as a whole, and the economic viability of alternative delivery strategies, according to different stakeholder perspectives.</p>
            </sec>
          </body>
          <back>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>XR-NTX</term>
                  <def>
                    <p id="Par4">Extended-release naltrexone</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NIDA</term>
                  <def>
                    <p id="Par5">National Institute of Drug Abuse</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ED</term>
                  <def>
                    <p id="Par6">Emergency department</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DATCAP</term>
                  <def>
                    <p id="Par7">Drug Abuse Treatment Cost Analysis Program</p>
                  </def>
                </def-item>
                <def-item>
                  <term>T-MSIS</term>
                  <def>
                    <p id="Par8">Transformed Medicaid Statistical Information System</p>
                  </def>
                </def-item>
                <def-item>
                  <term>NMOS</term>
                  <def>
                    <p id="Par9">Non-study Medical and Other Services</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TLFB</term>
                  <def>
                    <p id="Par10">Timeline follow back</p>
                  </def>
                </def-item>
                <def-item>
                  <term>HRQoL</term>
                  <def>
                    <p id="Par11">Health-related quality-of-life</p>
                  </def>
                </def-item>
                <def-item>
                  <term>QALY</term>
                  <def>
                    <p id="Par12">Quality adjusted life year</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CLAF</term>
                  <def>
                    <p id="Par13">Criminal and Legal Activities Form</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ASI</term>
                  <def>
                    <p id="Par14">Addiction Severity Index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DSM-5</term>
                  <def>
                    <p id="Par15">Diagnostic and Statistical Manual of Mental Disorders</p>
                  </def>
                </def-item>
                <def-item>
                  <term>BLS</term>
                  <def>
                    <p id="Par16">Bureau of Labor Statistics</p>
                  </def>
                </def-item>
                <def-item>
                  <term>ICER</term>
                  <def>
                    <p id="Par17">Incremental cost effectiveness ratio</p>
                  </def>
                </def-item>
                <def-item>
                  <term>GLMM</term>
                  <def>
                    <p id="Par18">Generalized linear mixed models</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EHR</term>
                  <def>
                    <p id="Par19">Electronic health record</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <fn-group>
              <fn>
                <p>
                  <bold>Publisher's Note</bold>
                </p>
                <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
              </fn>
            </fn-group>
            <ack>
              <title>Acknowledgements</title>
              <p>The authors would like to thank Danielle Ryan for her assistance with preparing the manuscript for publication.</p>
            </ack>
            <notes notes-type="author-contribution">
              <title>Authors’ contributions</title>
              <p>SMM, MSG, GEW, and DP conceived of the study. All authors are contributing to data collection. SMM wrote the manuscript first draft. All authors read and approved the final manuscript.</p>
            </notes>
            <notes notes-type="funding-information">
              <title>Funding</title>
              <p>By grants R01DA046721, R01DA040636, and P30DA040500 from the National Institute on Drug Abuse (NIDA) of the National Institutes of Health (NIH).</p>
            </notes>
            <notes notes-type="data-availability">
              <title>Availability of data and materials</title>
              <p>Not Applicable.</p>
            </notes>
            <notes>
              <title>Ethics approval and consent to participate</title>
              <p id="Par52">Not Applicable.</p>
            </notes>
            <notes>
              <title>Consent for publication</title>
              <p id="Par53">Not Applicable.</p>
            </notes>
            <notes notes-type="COI-statement">
              <title>Competing interests</title>
              <p id="Par54">Dr. Murphy reports grants from NIH during the conduct of the study, and having consulted for Sandoz Inc. outside the submitted work. Authors not named here have disclosed no conflicts of interest. Drs. Gordon and Woody are receiving in-kind study drug from Alkermes.</p>
            </notes>
            <ref-list id="Bib1">
              <title>References</title>
              <ref id="CR1">
                <label>1.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>Center for Behavioral Health Statistics and Quality</collab>
                  </person-group>
                  <source>Results from the 2016 National Survey on Drug Use and Health: detailed tables</source>
                  <year>2017</year>
                  <publisher-loc>Rockville</publisher-loc>
                  <publisher-name>Substance Abuse and Mental Health Services Administration</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR2">
                <label>2.</label>
                <mixed-citation publication-type="other">Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2017. Hyattsville, MD: Centers for Disease Control and Prevention, National Center for Health Statistics. Contract No.: NCHS Data Brief, no 329; 2018.</mixed-citation>
              </ref>
              <ref id="CR3">
                <label>3.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Birnbaum</surname>
                      <given-names>HG</given-names>
                    </name>
                    <name>
                      <surname>White</surname>
                      <given-names>AG</given-names>
                    </name>
                    <name>
                      <surname>Schiller</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Waldman</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Cleveland</surname>
                      <given-names>JM</given-names>
                    </name>
                    <name>
                      <surname>Roland</surname>
                      <given-names>CL</given-names>
                    </name>
                  </person-group>
                  <article-title>Societal costs of prescription opioid abuse, dependence, and misuse in the United States</article-title>
                  <source>Pain Med.</source>
                  <year>2011</year>
                  <volume>12</volume>
                  <issue>4</issue>
                  <fpage>657</fpage>
                  <lpage>667</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1526-4637.2011.01075.x</pub-id>
                  <?supplied-pmid 21392250?>
                  <pub-id pub-id-type="pmid">21392250</pub-id>
                </element-citation>
              </ref>
              <ref id="CR4">
                <label>4.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Catalano</surname>
                      <given-names>RF</given-names>
                    </name>
                    <name>
                      <surname>White</surname>
                      <given-names>HR</given-names>
                    </name>
                    <name>
                      <surname>Fleming</surname>
                      <given-names>CB</given-names>
                    </name>
                    <name>
                      <surname>Haggerty</surname>
                      <given-names>KP</given-names>
                    </name>
                  </person-group>
                  <article-title>Is nonmedical prescription opiate use a unique form of illicit drug use?</article-title>
                  <source>Addict Behav</source>
                  <year>2011</year>
                  <volume>36</volume>
                  <issue>1–2</issue>
                  <fpage>79</fpage>
                  <lpage>86</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.addbeh.2010.08.028</pub-id>
                  <?supplied-pmid 20864261?>
                  <pub-id pub-id-type="pmid">20864261</pub-id>
                </element-citation>
              </ref>
              <ref id="CR5">
                <label>5.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mark</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Woody</surname>
                      <given-names>GE</given-names>
                    </name>
                    <name>
                      <surname>Juday</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Kleber</surname>
                      <given-names>HD</given-names>
                    </name>
                  </person-group>
                  <article-title>The economic costs of heroin addiction in the United States</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2001</year>
                  <volume>61</volume>
                  <issue>2</issue>
                  <fpage>195</fpage>
                  <lpage>206</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0376-8716(00)00162-9</pub-id>
                </element-citation>
              </ref>
              <ref id="CR6">
                <label>6.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>McPherson</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>K</given-names>
                    </name>
                  </person-group>
                  <article-title>Nonmedical prescription opioid use and violent behavior among adolescents</article-title>
                  <source>J Child Adolesc Mental Health.</source>
                  <year>2014</year>
                  <volume>26</volume>
                  <issue>1</issue>
                  <fpage>35</fpage>
                  <lpage>47</lpage>
                  <pub-id pub-id-type="doi">10.2989/17280583.2013.849607</pub-id>
                </element-citation>
              </ref>
              <ref id="CR7">
                <label>7.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Polsky</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Economic evaluations of opioid use disorder interventions: a systematic review</article-title>
                  <source>Pharmacoeconomics.</source>
                  <year>2016</year>
                  <volume>34</volume>
                  <issue>9</issue>
                  <fpage>863</fpage>
                  <lpage>867</lpage>
                  <pub-id pub-id-type="doi">10.1007/s40273-016-0400-5</pub-id>
                  <?supplied-pmid 27002518?>
                  <pub-id pub-id-type="pmid">27002518</pub-id>
                </element-citation>
              </ref>
              <ref id="CR8">
                <label>8.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Compton</surname>
                      <given-names>WM</given-names>
                    </name>
                    <name>
                      <surname>Dawson</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Duffy</surname>
                      <given-names>SQ</given-names>
                    </name>
                    <name>
                      <surname>Grant</surname>
                      <given-names>BF</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of inmate populations on estimates of DSM-IV alcohol and drug use disorders in the United States</article-title>
                  <source>Am J Psychiatry.</source>
                  <year>2010</year>
                  <volume>167</volume>
                  <issue>4</issue>
                  <fpage>473</fpage>
                  <lpage>475</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09081087</pub-id>
                  <?supplied-pmid 20360330?>
                  <pub-id pub-id-type="pmid">20360330</pub-id>
                </element-citation>
              </ref>
              <ref id="CR9">
                <label>9.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Field</surname>
                      <given-names>G</given-names>
                    </name>
                  </person-group>
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Knight</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Farabee</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <article-title>Continuity of offender treatment: from the institution to the community</article-title>
                  <source>Treating addicted offenders: a continuum of effective practices</source>
                  <year>2004</year>
                  <publisher-loc>Kingston</publisher-loc>
                  <publisher-name>Civic Research Institute</publisher-name>
                  <fpage>1</fpage>
                  <lpage>9</lpage>
                </element-citation>
              </ref>
              <ref id="CR10">
                <label>10.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shivy</surname>
                      <given-names>VA</given-names>
                    </name>
                    <name>
                      <surname>Wu</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Moon</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Mann</surname>
                      <given-names>SC</given-names>
                    </name>
                    <name>
                      <surname>Holland</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Eacho</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Ex-offenders reentering the workforce</article-title>
                  <source>J Counsel Psychol.</source>
                  <year>2007</year>
                  <volume>54</volume>
                  <issue>4</issue>
                  <fpage>466</fpage>
                  <pub-id pub-id-type="doi">10.1037/0022-0167.54.4.466</pub-id>
                </element-citation>
              </ref>
              <ref id="CR11">
                <label>11.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Volkow</surname>
                      <given-names>ND</given-names>
                    </name>
                    <name>
                      <surname>Wang</surname>
                      <given-names>G-J</given-names>
                    </name>
                    <name>
                      <surname>Telang</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Fowler</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Logan</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Childress</surname>
                      <given-names>A-R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction</article-title>
                  <source>J Neurosci.</source>
                  <year>2006</year>
                  <volume>26</volume>
                  <issue>24</issue>
                  <fpage>6583</fpage>
                  <lpage>6588</lpage>
                  <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1544-06.2006</pub-id>
                  <?supplied-pmid 16775146?>
                  <pub-id pub-id-type="pmid">16775146</pub-id>
                </element-citation>
              </ref>
              <ref id="CR12">
                <label>12.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>McDonald</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Grossman</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>McNeely</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Laska</surname>
                      <given-names>E</given-names>
                    </name>
                    <name>
                      <surname>Rotrosen</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial</article-title>
                  <source>Addiction</source>
                  <year>2015</year>
                  <volume>110</volume>
                  <issue>6</issue>
                  <fpage>1008</fpage>
                  <lpage>1014</lpage>
                  <pub-id pub-id-type="doi">10.1111/add.12894</pub-id>
                  <?supplied-pmid 25703440?>
                  <pub-id pub-id-type="pmid">25703440</pub-id>
                </element-citation>
              </ref>
              <ref id="CR13">
                <label>13.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kinlock</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Gordon</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>O’Grady</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Fitzgerald</surname>
                      <given-names>TT</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2007</year>
                  <volume>91</volume>
                  <issue>2</issue>
                  <fpage>220</fpage>
                  <lpage>227</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2007.05.022</pub-id>
                </element-citation>
              </ref>
              <ref id="CR14">
                <label>14.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Binswanger</surname>
                      <given-names>IA</given-names>
                    </name>
                    <name>
                      <surname>Blatchford</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Mueller</surname>
                      <given-names>SR</given-names>
                    </name>
                    <name>
                      <surname>Stern</surname>
                      <given-names>MF</given-names>
                    </name>
                  </person-group>
                  <article-title>Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009</article-title>
                  <source>Ann Intern Med</source>
                  <year>2013</year>
                  <volume>159</volume>
                  <issue>9</issue>
                  <fpage>592</fpage>
                  <lpage>600</lpage>
                  <pub-id pub-id-type="doi">10.7326/0003-4819-159-9-201311050-00005</pub-id>
                  <?supplied-pmid 24189594?>
                  <pub-id pub-id-type="pmid">24189594</pub-id>
                </element-citation>
              </ref>
              <ref id="CR15">
                <label>15.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Pizzicato</surname>
                      <given-names>LN</given-names>
                    </name>
                    <name>
                      <surname>Drake</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Domer-Shank</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Johnson</surname>
                      <given-names>CC</given-names>
                    </name>
                    <name>
                      <surname>Viner</surname>
                      <given-names>KM</given-names>
                    </name>
                  </person-group>
                  <article-title>Beyond the walls: risk factors for overdose mortality following release from the philadelphia department of prisons</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2018</year>
                  <volume>189</volume>
                  <fpage>108</fpage>
                  <lpage>115</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.04.034</pub-id>
                </element-citation>
              </ref>
              <ref id="CR16">
                <label>16.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Ranapurwala</surname>
                      <given-names>SI</given-names>
                    </name>
                    <name>
                      <surname>Shanahan</surname>
                      <given-names>ME</given-names>
                    </name>
                    <name>
                      <surname>Alexandridis</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Proescholdbell</surname>
                      <given-names>SK</given-names>
                    </name>
                    <name>
                      <surname>Naumann</surname>
                      <given-names>RB</given-names>
                    </name>
                    <name>
                      <surname>Edwards</surname>
                      <given-names>D</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Opioid overdose mortality among former North Carolina inmates: 2000–2015</article-title>
                  <source>Am J Public Health</source>
                  <year>2018</year>
                  <volume>108</volume>
                  <issue>9</issue>
                  <fpage>1207</fpage>
                  <lpage>1213</lpage>
                  <pub-id pub-id-type="doi">10.2105/AJPH.2018.304514</pub-id>
                  <?supplied-pmid 30024795?>
                  <pub-id pub-id-type="pmid">30024795</pub-id>
                </element-citation>
              </ref>
              <ref id="CR17">
                <label>17.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Olsen</surname>
                      <given-names>Y</given-names>
                    </name>
                    <name>
                      <surname>Sharfstein</surname>
                      <given-names>JM</given-names>
                    </name>
                  </person-group>
                  <source>The opioid epidemic: what everyone needs to know</source>
                  <year>2019</year>
                  <publisher-loc>New York</publisher-loc>
                  <publisher-name>Oxford University Press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR18">
                <label>18.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gordon</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Kinlock</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Fitzgerald</surname>
                      <given-names>TT</given-names>
                    </name>
                    <name>
                      <surname>O’Grady</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Vocci</surname>
                      <given-names>FJ</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2014</year>
                  <volume>142</volume>
                  <fpage>33</fpage>
                  <lpage>40</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.05.011</pub-id>
                </element-citation>
              </ref>
              <ref id="CR19">
                <label>19.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Magura</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Hershberger</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Joseph</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Marsch</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Shropshire</surname>
                      <given-names>C</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2009</year>
                  <volume>99</volume>
                  <issue>1</issue>
                  <fpage>222</fpage>
                  <lpage>230</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2008.08.006</pub-id>
                </element-citation>
              </ref>
              <ref id="CR20">
                <label>20.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Carroll</surname>
                      <given-names>KM</given-names>
                    </name>
                    <name>
                      <surname>Ball</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Martino</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Nich</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Babuscio</surname>
                      <given-names>TA</given-names>
                    </name>
                    <name>
                      <surname>Nuro</surname>
                      <given-names>KF</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Computer-assisted delivery of cognitive-behavioral therapy for addiction: a randomized trial of CBT4CBT</article-title>
                  <source>Am J Psychiatry</source>
                  <year>2008</year>
                  <volume>165</volume>
                  <issue>7</issue>
                  <fpage>881</fpage>
                  <lpage>888</lpage>
                  <pub-id pub-id-type="doi">10.1176/appi.ajp.2008.07111835</pub-id>
                  <?supplied-pmid 18450927?>
                  <pub-id pub-id-type="pmid">18450927</pub-id>
                </element-citation>
              </ref>
              <ref id="CR21">
                <label>21.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kinlock</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Gordon</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Fitzgerald</surname>
                      <given-names>TT</given-names>
                    </name>
                    <name>
                      <surname>O’Grady</surname>
                      <given-names>KE</given-names>
                    </name>
                  </person-group>
                  <article-title>A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease</article-title>
                  <source>J Subst Abuse Treat</source>
                  <year>2009</year>
                  <volume>37</volume>
                  <issue>3</issue>
                  <fpage>277</fpage>
                  <lpage>285</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.jsat.2009.03.002</pub-id>
                  <?supplied-pmid 19339140?>
                  <pub-id pub-id-type="pmid">19339140</pub-id>
                </element-citation>
              </ref>
              <ref id="CR22">
                <label>22.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gordon</surname>
                      <given-names>MS</given-names>
                    </name>
                    <name>
                      <surname>Kinlock</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>RP</given-names>
                    </name>
                    <name>
                      <surname>Couvillion</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Sudec</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>O’Grady</surname>
                      <given-names>KE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Buprenorphine treatment for probationers and parolees</article-title>
                  <source>Subst Abus.</source>
                  <year>2015</year>
                  <volume>36</volume>
                  <issue>2</issue>
                  <fpage>217</fpage>
                  <lpage>225</lpage>
                  <pub-id pub-id-type="doi">10.1080/08897077.2014.902787</pub-id>
                  <?supplied-pmid 24701967?>
                  <pub-id pub-id-type="pmid">24701967</pub-id>
                </element-citation>
              </ref>
              <ref id="CR23">
                <label>23.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nunn</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Zaller</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Dickman</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Trimbur</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Nijhawan</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Rich</surname>
                      <given-names>JD</given-names>
                    </name>
                  </person-group>
                  <article-title>Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2009</year>
                  <volume>105</volume>
                  <issue>1</issue>
                  <fpage>83</fpage>
                  <lpage>88</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.06.015</pub-id>
                </element-citation>
              </ref>
              <ref id="CR24">
                <label>24.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rich</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Boutwell</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Shield</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Key</surname>
                      <given-names>RG</given-names>
                    </name>
                    <name>
                      <surname>McKenzie</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Clarke</surname>
                      <given-names>JG</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Attitudes and practices regarding the use of methadone in US state and federal prisons</article-title>
                  <source>J Urban Health.</source>
                  <year>2005</year>
                  <volume>82</volume>
                  <issue>3</issue>
                  <fpage>411</fpage>
                  <lpage>419</lpage>
                  <pub-id pub-id-type="doi">10.1093/jurban/jti072</pub-id>
                  <?supplied-pmid 15917502?>
                  <pub-id pub-id-type="pmid">15917502</pub-id>
                </element-citation>
              </ref>
              <ref id="CR25">
                <label>25.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mumola</surname>
                      <given-names>CJ</given-names>
                    </name>
                    <name>
                      <surname>Karberg</surname>
                      <given-names>JC</given-names>
                    </name>
                  </person-group>
                  <source>Drug use and dependence, state and federal prisoners, 2004</source>
                  <year>2006</year>
                  <publisher-loc>Washington, D.C.</publisher-loc>
                  <publisher-name>Department of Justice, Programs OoJ</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR26">
                <label>26.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Friedmann</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Hoskinson</surname>
                      <given-names>R</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Gordon</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schwartz</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Kinlock</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Knight</surname>
                      <given-names>K</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions</article-title>
                  <source>Subst Abus.</source>
                  <year>2012</year>
                  <volume>33</volume>
                  <issue>1</issue>
                  <fpage>9</fpage>
                  <lpage>18</lpage>
                  <pub-id pub-id-type="doi">10.1080/08897077.2011.611460</pub-id>
                  <?supplied-pmid 22263709?>
                  <pub-id pub-id-type="pmid">22263709</pub-id>
                </element-citation>
              </ref>
              <ref id="CR27">
                <label>27.</label>
                <mixed-citation publication-type="other">Substance Abuse and Mental Health Services Administration. Medication Assisted Treatment. 2016. <ext-link ext-link-type="uri" xlink:href="http://www.samhsa.gov/medication-assisted-treatment">http://www.samhsa.gov/medication-assisted-treatment</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR28">
                <label>28.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Krawczyk</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>Picher</surname>
                      <given-names>CE</given-names>
                    </name>
                    <name>
                      <surname>Feder</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Saloner</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <article-title>Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine</article-title>
                  <source>Health Aff.</source>
                  <year>2017</year>
                  <volume>36</volume>
                  <issue>12</issue>
                  <fpage>2046</fpage>
                  <lpage>2053</lpage>
                  <pub-id pub-id-type="doi">10.1377/hlthaff.2017.0890</pub-id>
                </element-citation>
              </ref>
              <ref id="CR29">
                <label>29.</label>
                <mixed-citation publication-type="other">Medication-assisted treatment for opioid addiction. Office of National Drug Control Policy; 2012.</mixed-citation>
              </ref>
              <ref id="CR30">
                <label>30.</label>
                <mixed-citation publication-type="other">Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration (SAMHSA); 2004.</mixed-citation>
              </ref>
              <ref id="CR31">
                <label>31.</label>
                <mixed-citation publication-type="other">IBM Micromedex<sup>®</sup> RED BOOK<sup>®</sup> (electronic version). Red Book Greenwood Village, Colorado: IBM Watson Health; 2019. <ext-link ext-link-type="uri" xlink:href="https://www.micromedexsolutions.com/">https://www.micromedexsolutions.com/</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR32">
                <label>32.</label>
                <mixed-citation publication-type="other">U.S. Department of Veterans Affairs Federal Supply Schedule Services 2019. <ext-link ext-link-type="uri" xlink:href="https://www.fss.va.gov">https://www.fss.va.gov</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR33">
                <label>33.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <collab>Physician’s Desk Reference</collab>
                  </person-group>
                  <source>Red Book: Pharmacy’s Fundamental Reference</source>
                  <year>2010</year>
                  <publisher-loc>Montvale</publisher-loc>
                  <publisher-name>Thomson Reuters</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR34">
                <label>34.</label>
                <mixed-citation publication-type="other">The Pew Charitable Trusts. Prison Health Care: Costs and Quality. 2017.</mixed-citation>
              </ref>
              <ref id="CR35">
                <label>35.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Håkansson</surname>
                      <given-names>A</given-names>
                    </name>
                    <name>
                      <surname>Berglund</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Risk factors for criminal recidivism–a prospective follow-up study in prisoners with substance abuse</article-title>
                  <source>BMC Psychiatry.</source>
                  <year>2012</year>
                  <volume>12</volume>
                  <issue>1</issue>
                  <fpage>1</fpage>
                  <pub-id pub-id-type="doi">10.1186/1471-244X-12-111</pub-id>
                  <pub-id pub-id-type="pmid">22230388</pub-id>
                </element-citation>
              </ref>
              <ref id="CR36">
                <label>36.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Durose</surname>
                      <given-names>MR</given-names>
                    </name>
                    <name>
                      <surname>Cooper</surname>
                      <given-names>AD</given-names>
                    </name>
                    <name>
                      <surname>Snyder</surname>
                      <given-names>HN</given-names>
                    </name>
                  </person-group>
                  <source>Recidivism of prisoners released in 30 states in 2005 patterns from 2005 to 2010</source>
                  <year>2014</year>
                  <publisher-loc>Washington, DC</publisher-loc>
                  <publisher-name>Bureau of Justice Statistics</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR37">
                <label>37.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Neumann</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Sanders</surname>
                      <given-names>GD</given-names>
                    </name>
                    <name>
                      <surname>Russell</surname>
                      <given-names>LB</given-names>
                    </name>
                    <name>
                      <surname>Siegel</surname>
                      <given-names>JE</given-names>
                    </name>
                    <name>
                      <surname>Ganiats</surname>
                      <given-names>TG</given-names>
                    </name>
                  </person-group>
                  <source>Cost-effectiveness in health and medicine</source>
                  <year>2017</year>
                  <edition>2</edition>
                  <publisher-loc>New York</publisher-loc>
                  <publisher-name>Oxford University Press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR38">
                <label>38.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Glick</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Doshi</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Sonnad</surname>
                      <given-names>SS</given-names>
                    </name>
                    <name>
                      <surname>Polsky</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <source>Economic evaluation in clinical trials</source>
                  <year>2014</year>
                  <publisher-loc>Oxford</publisher-loc>
                  <publisher-name>Oxford University Press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR39">
                <label>39.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drummond</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Schulpher</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Claxton</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Stoddart</surname>
                      <given-names>GL</given-names>
                    </name>
                    <name>
                      <surname>Torrance</surname>
                      <given-names>GW</given-names>
                    </name>
                  </person-group>
                  <source>Methods for the economic evaluation of health care programmes</source>
                  <year>2015</year>
                  <edition>4</edition>
                  <publisher-loc>Oxford</publisher-loc>
                  <publisher-name>Oxford University Press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR40">
                <label>40.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Polsky</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Friedmann</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Kinlock</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Nunes</surname>
                      <given-names>EV</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cost-effectiveness of extended release naltrexone to prevent relapse among criminal-justice-involved persons with a history of opioid use disorder</article-title>
                  <source>Addiction</source>
                  <year>2017</year>
                  <volume>112</volume>
                  <issue>8</issue>
                  <fpage>1440</fpage>
                  <lpage>1450</lpage>
                  <pub-id pub-id-type="doi">10.1111/add.13807</pub-id>
                  <?supplied-pmid 28239984?>
                  <pub-id pub-id-type="pmid">28239984</pub-id>
                </element-citation>
              </ref>
              <ref id="CR41">
                <label>41.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lee</surname>
                      <given-names>JD</given-names>
                    </name>
                    <name>
                      <surname>Friedmann</surname>
                      <given-names>PD</given-names>
                    </name>
                    <name>
                      <surname>Kinlock</surname>
                      <given-names>TW</given-names>
                    </name>
                    <name>
                      <surname>Nunes</surname>
                      <given-names>EV</given-names>
                    </name>
                    <name>
                      <surname>Boney</surname>
                      <given-names>TY</given-names>
                    </name>
                    <name>
                      <surname>Hoskinson</surname>
                      <given-names>RA</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Extended-release naltrexone to prevent opioid relapse in criminal justice offenders</article-title>
                  <source>N Engl J Med</source>
                  <year>2016</year>
                  <volume>374</volume>
                  <issue>13</issue>
                  <fpage>1232</fpage>
                  <lpage>1242</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMoa1505409</pub-id>
                  <?supplied-pmid 27028913?>
                  <pub-id pub-id-type="pmid">27028913</pub-id>
                </element-citation>
              </ref>
              <ref id="CR42">
                <label>42.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drummond</surname>
                      <given-names>MF</given-names>
                    </name>
                    <name>
                      <surname>Davies</surname>
                      <given-names>L</given-names>
                    </name>
                  </person-group>
                  <article-title>Economic analysis alongside clinical trials</article-title>
                  <source>Int J Technol Assess Health Care</source>
                  <year>1991</year>
                  <volume>7</volume>
                  <issue>4</issue>
                  <fpage>561</fpage>
                  <lpage>573</lpage>
                  <pub-id pub-id-type="doi">10.1017/S0266462300007121</pub-id>
                  <?supplied-pmid 1778701?>
                  <pub-id pub-id-type="pmid">1778701</pub-id>
                </element-citation>
              </ref>
              <ref id="CR43">
                <label>43.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>French</surname>
                      <given-names>MT</given-names>
                    </name>
                  </person-group>
                  <source>Drug Abuse Treatment Cost Anslysis Program (DATCAP): User’s Manual</source>
                  <year>2003</year>
                  <publisher-loc>Florida</publisher-loc>
                  <publisher-name>University of Miami</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR44">
                <label>44.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>French</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Dunlap</surname>
                      <given-names>LJ</given-names>
                    </name>
                    <name>
                      <surname>Zarkin</surname>
                      <given-names>GA</given-names>
                    </name>
                    <name>
                      <surname>McGeary</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>McLellan</surname>
                      <given-names>AT</given-names>
                    </name>
                  </person-group>
                  <article-title>A structured instrument for estimating the economic cost of drug abuse treatment: the Drug Abuse Treatment Cost Analysis Program (DATCAP)</article-title>
                  <source>J Subst Abuse Treat</source>
                  <year>1997</year>
                  <volume>14</volume>
                  <issue>5</issue>
                  <fpage>445</fpage>
                  <lpage>455</lpage>
                  <pub-id pub-id-type="doi">10.1016/S0740-5472(97)00132-3</pub-id>
                  <?supplied-pmid 9437614?>
                  <pub-id pub-id-type="pmid">9437614</pub-id>
                </element-citation>
              </ref>
              <ref id="CR45">
                <label>45.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Sobell</surname>
                      <given-names>LC</given-names>
                    </name>
                    <name>
                      <surname>Sobell</surname>
                      <given-names>MB</given-names>
                    </name>
                  </person-group>
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Litten</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>J</given-names>
                    </name>
                  </person-group>
                  <article-title>Timeline follow-back: a technique for assessing self-reported alcohol consumption</article-title>
                  <source>Measuring Alcohol Consumption</source>
                  <year>1992</year>
                  <publisher-loc>Berlin</publisher-loc>
                  <publisher-name>Springer</publisher-name>
                  <fpage>41</fpage>
                  <lpage>72</lpage>
                </element-citation>
              </ref>
              <ref id="CR46">
                <label>46.</label>
                <mixed-citation publication-type="other">Brown JB, Adams ME. Patients as reliable reporters of medical care process: recall of ambulatory encounter events. Med Care. 1992:400–11.</mixed-citation>
              </ref>
              <ref id="CR47">
                <label>47.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Harlow</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Linet</surname>
                      <given-names>MS</given-names>
                    </name>
                  </person-group>
                  <article-title>Agreement between questionnaire data and medical records: the evidence for accuracy of recall</article-title>
                  <source>Am J Epidemiol</source>
                  <year>1989</year>
                  <volume>129</volume>
                  <issue>2</issue>
                  <fpage>233</fpage>
                  <lpage>248</lpage>
                  <pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a115129</pub-id>
                  <?supplied-pmid 2643301?>
                  <pub-id pub-id-type="pmid">2643301</pub-id>
                </element-citation>
              </ref>
              <ref id="CR48">
                <label>48.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Roberts</surname>
                      <given-names>RO</given-names>
                    </name>
                    <name>
                      <surname>Bergstralh</surname>
                      <given-names>EJ</given-names>
                    </name>
                    <name>
                      <surname>Schmidt</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Jacobsen</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Comparison of self-reported and medical record health care utilization measures</article-title>
                  <source>J Clin Epidemiol</source>
                  <year>1996</year>
                  <volume>49</volume>
                  <issue>9</issue>
                  <fpage>989</fpage>
                  <lpage>995</lpage>
                  <pub-id pub-id-type="doi">10.1016/0895-4356(96)00143-6</pub-id>
                  <?supplied-pmid 8780606?>
                  <pub-id pub-id-type="pmid">8780606</pub-id>
                </element-citation>
              </ref>
              <ref id="CR49">
                <label>49.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Wallihan</surname>
                      <given-names>DB</given-names>
                    </name>
                    <name>
                      <surname>Stump</surname>
                      <given-names>TE</given-names>
                    </name>
                    <name>
                      <surname>Callahan</surname>
                      <given-names>CM</given-names>
                    </name>
                  </person-group>
                  <article-title>Accuracy of self-reported health services use and patterns of care among urban older adults</article-title>
                  <source>Med Care</source>
                  <year>1999</year>
                  <volume>37</volume>
                  <issue>7</issue>
                  <fpage>662</fpage>
                  <lpage>670</lpage>
                  <pub-id pub-id-type="doi">10.1097/00005650-199907000-00006</pub-id>
                  <?supplied-pmid 10424637?>
                  <pub-id pub-id-type="pmid">10424637</pub-id>
                </element-citation>
              </ref>
              <ref id="CR50">
                <label>50.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Campbell</surname>
                      <given-names>AN</given-names>
                    </name>
                    <name>
                      <surname>Ghitza</surname>
                      <given-names>UE</given-names>
                    </name>
                    <name>
                      <surname>Kyle</surname>
                      <given-names>TL</given-names>
                    </name>
                    <name>
                      <surname>Bailey</surname>
                      <given-names>GL</given-names>
                    </name>
                    <name>
                      <surname>Nunes</surname>
                      <given-names>EV</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cost-effectiveness of an internet-delivered treatment for substance abuse: data from a multisite randomized controlled trial</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2016</year>
                  <volume>161</volume>
                  <fpage>119</fpage>
                  <lpage>126</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2016.01.021</pub-id>
                </element-citation>
              </ref>
              <ref id="CR51">
                <label>51.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>McCollister</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Leff</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Jeng</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>JD</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cost-effectiveness of buprenorphine-naloxone versus extended-release naltrexone to prevent opioid relapse</article-title>
                  <source>Ann Intern Med</source>
                  <year>2019</year>
                  <volume>170</volume>
                  <fpage>90</fpage>
                  <lpage>98</lpage>
                  <pub-id pub-id-type="doi">10.7326/M18-0227</pub-id>
                  <?supplied-pmid 30557443?>
                  <pub-id pub-id-type="pmid">30557443</pub-id>
                </element-citation>
              </ref>
              <ref id="CR52">
                <label>52.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Polsky</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Glick</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Subramaniam</surname>
                      <given-names>GA</given-names>
                    </name>
                    <name>
                      <surname>Poole</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Woody</surname>
                      <given-names>GE</given-names>
                    </name>
                  </person-group>
                  <article-title>Cost-effectiveness of extended buprenorphine–naloxone treatment for opioid-dependent youth: data from a randomized trial</article-title>
                  <source>Addiction</source>
                  <year>2010</year>
                  <volume>105</volume>
                  <issue>9</issue>
                  <fpage>1616</fpage>
                  <lpage>1624</lpage>
                  <pub-id pub-id-type="doi">10.1111/j.1360-0443.2010.03001.x</pub-id>
                  <?supplied-pmid 20626379?>
                  <pub-id pub-id-type="pmid">20626379</pub-id>
                </element-citation>
              </ref>
              <ref id="CR53">
                <label>53.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gutkind</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Schackman</surname>
                      <given-names>BR</given-names>
                    </name>
                    <name>
                      <surname>Morgan</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Leff</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Agyemang</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cost-effectiveness of HCV treatment models for people who inject drugs in opioid agonist treatment programs</article-title>
                  <source>Clin Infect Dis.</source>
                  <year>2019</year>
                  <volume>70</volume>
                  <issue>7</issue>
                  <fpage>1397</fpage>
                  <lpage>1405</lpage>
                </element-citation>
              </ref>
              <ref id="CR54">
                <label>54.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dolan</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Modeling valuations for EuroQol health states</article-title>
                  <source>Med Care</source>
                  <year>1997</year>
                  <volume>35</volume>
                  <issue>11</issue>
                  <fpage>1095</fpage>
                  <lpage>1108</lpage>
                  <pub-id pub-id-type="doi">10.1097/00005650-199711000-00002</pub-id>
                  <?supplied-pmid 9366889?>
                  <pub-id pub-id-type="pmid">9366889</pub-id>
                </element-citation>
              </ref>
              <ref id="CR55">
                <label>55.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <collab>The EuroQol Group</collab>
                  </person-group>
                  <article-title>EuroQol-a new facility for the measurement of health-related quality of life</article-title>
                  <source>Health Policy</source>
                  <year>1990</year>
                  <volume>16</volume>
                  <issue>3</issue>
                  <fpage>199</fpage>
                  <lpage>208</lpage>
                  <pub-id pub-id-type="doi">10.1016/0168-8510(90)90421-9</pub-id>
                  <pub-id pub-id-type="pmid">10109801</pub-id>
                </element-citation>
              </ref>
              <ref id="CR56">
                <label>56.</label>
                <mixed-citation publication-type="other">EuroQol. EQ-5D 2019. <ext-link ext-link-type="uri" xlink:href="https://euroqol.org">https://euroqol.org</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR57">
                <label>57.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Richardson</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Mckie</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Bariola</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Culyer</surname>
                      <given-names>AJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Multiattribute utility instruments and their use</article-title>
                  <source>Encylopedia of Health Economics</source>
                  <year>2014</year>
                  <publisher-loc>Amsterdam</publisher-loc>
                  <publisher-name>Elsevier</publisher-name>
                  <fpage>341</fpage>
                  <lpage>357</lpage>
                </element-citation>
              </ref>
              <ref id="CR58">
                <label>58.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Thornberry</surname>
                      <given-names>TP</given-names>
                    </name>
                    <name>
                      <surname>Krohn</surname>
                      <given-names>MD</given-names>
                    </name>
                  </person-group>
                  <source>Comparison of self-report and official data for measuring crime. Measurement problems in criminal justice research: Workshop summary</source>
                  <year>2003</year>
                  <publisher-loc>Washington, DC</publisher-loc>
                  <publisher-name>National Academies Press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR59">
                <label>59.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nieves</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Draine</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Solomon</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>The validity of self-reported criminal arrest history among clients of a psychiatric probation and parole service</article-title>
                  <source>J Offender Rehabil.</source>
                  <year>2000</year>
                  <volume>30</volume>
                  <issue>3–4</issue>
                  <fpage>133</fpage>
                  <lpage>151</lpage>
                  <pub-id pub-id-type="doi">10.1300/J076v30n03_07</pub-id>
                </element-citation>
              </ref>
              <ref id="CR60">
                <label>60.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jansson</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Hesse</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Fridell</surname>
                      <given-names>M</given-names>
                    </name>
                  </person-group>
                  <article-title>Validity of self-reported criminal justice system involvement in substance abusing women at 5-year follow-up</article-title>
                  <source>BMC Psychiatry.</source>
                  <year>2008</year>
                  <volume>8</volume>
                  <issue>1</issue>
                  <fpage>2</fpage>
                  <pub-id pub-id-type="doi">10.1186/1471-244X-8-2</pub-id>
                  <?supplied-pmid 18179700?>
                  <pub-id pub-id-type="pmid">18179700</pub-id>
                </element-citation>
              </ref>
              <ref id="CR61">
                <label>61.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McCollister</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>X</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Leff</surname>
                      <given-names>JA</given-names>
                    </name>
                    <name>
                      <surname>Kronmal</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Chandler</surname>
                      <given-names>RK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Criminal justice measures for economic data harmonization in substance use disorder research</article-title>
                  <source>Health Justice</source>
                  <year>2018</year>
                  <volume>6</volume>
                  <issue>1</issue>
                  <fpage>17</fpage>
                  <pub-id pub-id-type="doi">10.1186/s40352-018-0073-6</pub-id>
                  <?supplied-pmid 30242561?>
                  <pub-id pub-id-type="pmid">30242561</pub-id>
                </element-citation>
              </ref>
              <ref id="CR62">
                <label>62.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McLellan</surname>
                      <given-names>AT</given-names>
                    </name>
                    <name>
                      <surname>Kushner</surname>
                      <given-names>H</given-names>
                    </name>
                    <name>
                      <surname>Metzger</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Peters</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Smith</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Grissom</surname>
                      <given-names>G</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The fifth edition of the addiction severity index</article-title>
                  <source>J Subst Abuse Treat</source>
                  <year>1992</year>
                  <volume>9</volume>
                  <issue>3</issue>
                  <fpage>199</fpage>
                  <lpage>213</lpage>
                  <pub-id pub-id-type="doi">10.1016/0740-5472(92)90062-S</pub-id>
                  <?supplied-pmid 1334156?>
                  <pub-id pub-id-type="pmid">1334156</pub-id>
                </element-citation>
              </ref>
              <ref id="CR63">
                <label>63.</label>
                <mixed-citation publication-type="other">American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC; 2013.</mixed-citation>
              </ref>
              <ref id="CR64">
                <label>64.</label>
                <mixed-citation publication-type="other">Centers for Medicare &amp; Medicaid Services. Transformed Medicaid Statistical Information System (T-MSIS) 2020. <ext-link ext-link-type="uri" xlink:href="https://www.medicaid.gov/medicaid/data-and-systems/macbis/tmsis/index.html">https://www.medicaid.gov/medicaid/data-and-systems/macbis/tmsis/index.html</ext-link>].</mixed-citation>
              </ref>
              <ref id="CR65">
                <label>65.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brady</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Robinson</surname>
                      <given-names>B</given-names>
                    </name>
                  </person-group>
                  <source>Medicare hospital prospective payment system: how DRG rates are calculated and updated</source>
                  <year>2001</year>
                  <publisher-loc>Washington, D.C.</publisher-loc>
                  <publisher-name>Health and Human Services Office of Inspector General, Office of Evaluations and Inspections</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR66">
                <label>66.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>McCollister</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>French</surname>
                      <given-names>MT</given-names>
                    </name>
                    <name>
                      <surname>Fang</surname>
                      <given-names>H</given-names>
                    </name>
                  </person-group>
                  <article-title>The cost of crime to society: new crime-specific estimates for policy and program evaluation</article-title>
                  <source>Drug Alcohol Depen.</source>
                  <year>2010</year>
                  <volume>108</volume>
                  <issue>1–2</issue>
                  <fpage>98</fpage>
                  <lpage>109</lpage>
                  <pub-id pub-id-type="doi">10.1016/j.drugalcdep.2009.12.002</pub-id>
                </element-citation>
              </ref>
              <ref id="CR67">
                <label>67.</label>
                <mixed-citation publication-type="other">Bureau of Labor Statistics. Occupational Outlook Handbook Washington, DC2018<ext-link ext-link-type="uri" xlink:href="http://www.bls.gov/ooh/home.htm">http://www.bls.gov/ooh/home.htm</ext-link>.</mixed-citation>
              </ref>
              <ref id="CR68">
                <label>68.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Card</surname>
                      <given-names>D</given-names>
                    </name>
                  </person-group>
                  <source>The causal effect of education on earnings</source>
                  <year>1999</year>
                  <publisher-loc>Oxford</publisher-loc>
                  <publisher-name>Elsevier</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR69">
                <label>69.</label>
                <mixed-citation publication-type="other">Max W, Rice DP, Sung H-Y, Michel M. Valuing human life: estimating the present value of lifetime earnings, 2000. University of California San Francisco: Center for Tobacco Control Research and Education; 2004.</mixed-citation>
              </ref>
              <ref id="CR70">
                <label>70.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Braithwaite</surname>
                      <given-names>RS</given-names>
                    </name>
                    <name>
                      <surname>Meltzer</surname>
                      <given-names>DO</given-names>
                    </name>
                    <name>
                      <surname>King</surname>
                      <given-names>JT</given-names>
                      <suffix>Jr</suffix>
                    </name>
                    <name>
                      <surname>Leslie</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>Roberts</surname>
                      <given-names>MS</given-names>
                    </name>
                  </person-group>
                  <article-title>What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?</article-title>
                  <source>Med Care</source>
                  <year>2008</year>
                  <volume>46</volume>
                  <issue>4</issue>
                  <fpage>349</fpage>
                  <lpage>356</lpage>
                  <pub-id pub-id-type="doi">10.1097/MLR.0b013e31815c31a7</pub-id>
                  <?supplied-pmid 18362813?>
                  <pub-id pub-id-type="pmid">18362813</pub-id>
                </element-citation>
              </ref>
              <ref id="CR71">
                <label>71.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Neumann</surname>
                      <given-names>PJ</given-names>
                    </name>
                    <name>
                      <surname>Cohen</surname>
                      <given-names>JT</given-names>
                    </name>
                    <name>
                      <surname>Weinstein</surname>
                      <given-names>MC</given-names>
                    </name>
                  </person-group>
                  <article-title>Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold</article-title>
                  <source>N Engl J Med</source>
                  <year>2014</year>
                  <volume>371</volume>
                  <issue>9</issue>
                  <fpage>796</fpage>
                  <lpage>797</lpage>
                  <pub-id pub-id-type="doi">10.1056/NEJMp1405158</pub-id>
                  <?supplied-pmid 25162885?>
                  <pub-id pub-id-type="pmid">25162885</pub-id>
                </element-citation>
              </ref>
              <ref id="CR72">
                <label>72.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Matthews</surname>
                      <given-names>JNS</given-names>
                    </name>
                    <name>
                      <surname>Altman</surname>
                      <given-names>DG</given-names>
                    </name>
                    <name>
                      <surname>Campbell</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Royston</surname>
                      <given-names>P</given-names>
                    </name>
                  </person-group>
                  <article-title>Analysis of serial measurements in medical research</article-title>
                  <source>Brit Med J.</source>
                  <year>1990</year>
                  <volume>300</volume>
                  <issue>6719</issue>
                  <fpage>230</fpage>
                  <lpage>235</lpage>
                  <pub-id pub-id-type="doi">10.1136/bmj.300.6719.230</pub-id>
                  <?supplied-pmid 2106931?>
                  <pub-id pub-id-type="pmid">2106931</pub-id>
                </element-citation>
              </ref>
              <ref id="CR73">
                <label>73.</label>
                <element-citation publication-type="journal">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Holder</surname>
                      <given-names>HD</given-names>
                    </name>
                    <name>
                      <surname>Cisler</surname>
                      <given-names>RA</given-names>
                    </name>
                    <name>
                      <surname>Longabaugh</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Stout</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Treno</surname>
                      <given-names>AJ</given-names>
                    </name>
                    <name>
                      <surname>Zweben</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <article-title>RESEARCH REPORT alcoholism treatment and medical care costs from project MATCH</article-title>
                  <source>Addiction</source>
                  <year>2000</year>
                  <volume>95</volume>
                  <issue>7</issue>
                  <fpage>999</fpage>
                  <lpage>1013</lpage>
                  <pub-id pub-id-type="doi">10.1046/j.1360-0443.2000.9579993.x</pub-id>
                  <?supplied-pmid 10962766?>
                  <pub-id pub-id-type="pmid">10962766</pub-id>
                </element-citation>
              </ref>
              <ref id="CR74">
                <label>74.</label>
                <element-citation publication-type="book">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Drummond</surname>
                      <given-names>MF</given-names>
                    </name>
                  </person-group>
                  <source>Methods for the economic evaluation of health care programmes</source>
                  <year>2005</year>
                  <publisher-loc>Oxford</publisher-loc>
                  <publisher-name>Oxford university press</publisher-name>
                </element-citation>
              </ref>
              <ref id="CR75">
                <label>75.</label>
                <mixed-citation publication-type="other">Vestal C. New momentum for addiction treatment behind bars. PEW; 2018.</mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
